Sui Yong-Gang, Teng Si-Yong, Qian Jie, Wu Yuan, Dou Ke-Fei, Tang Yi-Da, Qiao Shu-Bin, Wu Yong-Jian
Department of Cardiology, Fuwai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
J Int Med Res. 2019 Sep;47(9):4431-4441. doi: 10.1177/0300060519860969. Epub 2019 Jul 26.
To investigate what is the most appropriate strategy for patients with ST-segment elevation myocardial infarction (STEMI) aged ≥80 years in China.
This cohort study retrospectively enrolled patients with STEMI aged ≥80 years old and grouped them according to the treatment strategy that was used: a conservative treatment strategy or an invasive treatment strategy. Factors associated with whether to perform an invasive intervention, in-hospital death and a good prognosis were investigated using logistic regression analyses.
A total of 232 patients were enrolled: conservative treatment group ( = 93) and invasive treatment group ( = 139). Patients in the invasive treatment group had a better prognosis and lower incidence of adverse events compared with the conservative treatment group. Advanced age, creatinine level and a higher Killip class were inversely correlated with whether to perform an invasive intervention, while the use of beta-receptor-blocking agents was a favourable factor for invasive treatment. Hypertension and a higher Killip class were risk factors for in-hospital death, while the use of beta-receptor-blocking agents and diuretics decreased the risk of in-hospital death.
An invasive treatment strategy was superior to a conservative treatment strategy in patients with STEMI aged ≥80 years.
探讨中国≥80岁ST段抬高型心肌梗死(STEMI)患者最适宜的治疗策略。
本队列研究回顾性纳入≥80岁的STEMI患者,并根据所采用的治疗策略进行分组:保守治疗策略或侵入性治疗策略。采用逻辑回归分析研究与是否进行侵入性干预、院内死亡及良好预后相关的因素。
共纳入232例患者:保守治疗组(n = 93)和侵入性治疗组(n = 139)。与保守治疗组相比,侵入性治疗组患者预后更好,不良事件发生率更低。高龄、肌酐水平及较高的Killip分级与是否进行侵入性干预呈负相关,而使用β受体阻滞剂是侵入性治疗的有利因素。高血压和较高的Killip分级是院内死亡的危险因素,而使用β受体阻滞剂和利尿剂可降低院内死亡风险。
对于≥80岁的STEMI患者,侵入性治疗策略优于保守治疗策略。